Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9549036, 13 pages
http://dx.doi.org/10.1155/2016/9549036
Research Article

A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart

1Department of Oncology, University of Turin, 10126 Turin, Italy
2Department of Medical Sciences, University of Turin, 10126 Turin, Italy
3FPO-IRCCS, 10060 Candiolo, Italy
4Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy

Received 22 January 2016; Accepted 5 April 2016

Academic Editor: Oreste Gualillo

Copyright © 2016 Valentina Sala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Evans, J. E. Morley, J. Argilés et al., “Cachexia: a new definition,” Clinical Nutrition, vol. 27, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Anker, P. Ponikowski, S. Varney et al., “Wasting as independent risk factor for mortality in chronic heart failure,” The Lancet, vol. 349, no. 9058, pp. 1050–1053, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. S. von Haehling, M. Lainscak, J. Springer, and S. D. Anker, “Cardiac cachexia: a systematic overview,” Pharmacology and Therapeutics, vol. 121, no. 3, pp. 227–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. von Haehling, R. Stepney, and S. D. Anker, “Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference,” International Journal of Cardiology, vol. 144, no. 3, pp. 347–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. D. Anker, T. P. Chua, P. Ponikowski et al., “Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia,” Circulation, vol. 96, no. 2, pp. 526–534, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Anker, P. P. Ponikowski, A. L. Clark et al., “Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure,” European Heart Journal, vol. 20, no. 9, pp. 683–693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. McMillan, T. Preston, W. S. Watson et al., “Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer,” British Journal of Surgery, vol. 81, no. 7, pp. 1011–1014, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Farkas, S. von Haehling, K. Kalantar-Zadeh, J. E. Morley, S. D. Anker, and M. Lainscak, “Cachexia as a major public health problem: frequent, costly, and deadly,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 3, pp. 173–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Deboer, “Animal models of anorexia and cachexia,” Expert Opinion on Drug Discovery, vol. 4, no. 11, pp. 1145–1155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Konishi, N. Ebner, S. Von Haehling, S. D. Anker, and J. Springer, “Developing models for cachexia and their implications in drug discovery,” Expert Opinion on Drug Discovery, vol. 10, no. 7, pp. 743–752, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Li, R. E. Waters, S. I. Redfern et al., “Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice,” The American Journal of Pathology, vol. 170, no. 2, pp. 599–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Kato, S. Niizuma, Y. Inuzuka et al., “Analysis of liver metabolism in a rat model of heart failure,” International Journal of Cardiology, vol. 161, no. 3, pp. 130–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande Woude, “Met, metastasis, motility and more,” Nature Reviews Molecular Cell Biology, vol. 4, no. 12, pp. 915–925, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Leo, V. Sala, M. Morello et al., “Activated met signalling in the developing mouse heart leads to cardiac disease,” PLoS ONE, vol. 6, no. 2, Article ID e14675, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Peschard and M. Park, “From Tpr-Met to Met, tumorigenesis and tubes,” Oncogene, vol. 26, no. 9, pp. 1276–1285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Crepaldi, F. Bersani, C. Scuoppo et al., “Conditional activation of MET in differentiated skeletal muscle induces atrophy,” The Journal of Biological Chemistry, vol. 282, no. 9, pp. 6812–6822, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gatti, C. Leo, S. Gallo et al., “Gene expression profiling of HGF/Met activation in neonatal mouse heart,” Transgenic Research, vol. 22, no. 3, pp. 579–593, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Vinchi, L. De Franceschi, A. Ghigo et al., “Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases,” Circulation, vol. 127, no. 12, pp. 1317–1329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Ulitsky, A. Maron-Katz, S. Shavit et al., “Expander: from expression microarrays to networks and functions,” Nature Protocols, vol. 5, no. 2, pp. 303–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Gossen and H. Bujard, “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5547–5551, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Harjai, “Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen,” Annals of Internal Medicine, vol. 131, no. 5, pp. 376–386, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Shah, “Ventricular remodeling in heart failure with preserved ejection fraction,” Current Heart Failure Reports, vol. 10, no. 4, pp. 341–349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Shimano, N. Ouchi, and K. Walsh, “Cardiokines: recent progress in elucidating the cardiac secretome,” Circulation, vol. 126, no. 21, pp. e327–e332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Adela and S. K. Banerjee, “GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective,” Journal of Diabetes Research, vol. 2015, Article ID 490842, 14 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Cheng, K. M. Akkerhuis, L. C. Battes et al., “Biomarkers of heart failure with normal ejection fraction: a systematic review,” European Journal of Heart Failure, vol. 15, no. 12, pp. 1350–1362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. I. S. Anand, T. Kempf, T. S. Rector et al., “Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial,” Circulation, vol. 122, no. 14, pp. 1387–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Santhanakrishnan, J. P. Chong, T. P. Ng, L. H. Ling, D. Sim, K. T. Leong et al., “Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. Reduced ejection fraction,” European Journal of Heart Failure, vol. 14, no. 12, pp. 1338–1347, 2012. View at Publisher · View at Google Scholar
  28. J. Xu, T. R. Kimball, J. N. Lorenz et al., “GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation,” Circulation Research, vol. 98, no. 3, pp. 342–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Q. Khan, K. Ng, O. Dhillon et al., “Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction,” European Heart Journal, vol. 30, no. 9, pp. 1057–1065, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. V. W. W. Tsai, Y. Husaini, R. Manandhar et al., “Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15,” Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 4, pp. 239–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Welsh, L. M. Sapinoso, S. G. Kern et al., “Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3410–3415, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Johnen, S. Lin, T. Kuffner et al., “Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1,” Nature Medicine, vol. 13, no. 11, pp. 1333–1340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. D. Anker and A. J. S. Coats, “Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation,” Chest, vol. 115, no. 3, pp. 836–847, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Sala, S. Gallo, S. Gatti et al., “Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib,” Journal of Molecular and Cellular Cardiology, vol. 93, pp. 84–97, 2016. View at Publisher · View at Google Scholar
  35. P. C. Schulze, S. Gielen, V. Adams et al., “Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulin-like growth factor-I in chronic heart failure,” Basic Research in Cardiology, vol. 98, no. 4, pp. 267–274, 2003. View at Google Scholar · View at Scopus
  36. S. T. Isaac, T. C. Tan, and P. Polly, “Endoplasmic reticulum stress, calcium dysregulation and altered protein translation: intersection of processes that contribute to cancer cachexia induced skeletal muscle wasting,” Current Drug Targets, 2015. View at Google Scholar
  37. P. Costelli, R. D. Tullio, F. M. Baccino, and E. Melloni, “Activation of Ca2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia,” British Journal of Cancer, vol. 84, no. 7, pp. 946–950, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Doehner, M. Frenneaux, and S. D. Anker, “Metabolic impairment in heart failure: the myocardial and systemic perspective,” Journal of the American College of Cardiology, vol. 64, no. 13, pp. 1388–1400, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Adams, U. Späte, N. Kränkel et al., “Nuclear factor-kappa B activation in skeletal muscle of patients with chronic heart failure: correlation with the expression of inducible nitric oxide synthase,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 10, no. 4, pp. 273–277, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Cai, J. D. Frantz, N. E. Tawa Jr. et al., “IKKβ/NF-κB activation causes severe muscle wasting in mice,” Cell, vol. 119, no. 2, pp. 285–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. P. C. Schulze, S. Gielen, G. Schuler, and R. Hambrecht, “Chronic heart failure and skeletal muscle catabolism: effects of exercise training,” International Journal of Cardiology, vol. 85, no. 1, pp. 141–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Martins, R. Vitorino, D. Moreira-Gonçalves, F. Amado, J. A. Duarte, and R. Ferreira, “Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia,” Clinical Biochemistry, vol. 47, no. 1-2, pp. 8–15, 2014. View at Publisher · View at Google Scholar · View at Scopus